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Abstract
We analysed trends of human immunodeﬁciency virus type 1
(HIV-1) drug resistance during 2007–2009 in the Italian national
HIV drug resistance database ‘ARCA’. Prevalence of resistance
in each year was examined on the basis of the presence of
major International AIDS Society-2009 mutations. Predictors of
resistance were analysed by multivariable logistic regression.
Nine hundred and sixty-six patients were selected. Resistance to
nucleoside reverse transcriptase inhibitors and protease inhibi-
tors showed a signiﬁcant decline with respect to previous sur-
veys. Resistance to any class of drug and three drug classes
remained stable. Independent predictors of three-class resistance
were the number of treatment regimens experienced, prior sub-
optimal nucleoside reverse transcriptase inhibitor therapy and
the current use of ritonavir-boosted protease inhibitors.
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Background
The introduction of combination antiretroviral therapy
(cART) has dramatically improved the natural history and
prognosis of human immunodeﬁciency virus type 1 (HIV-1)
infection and AIDS [1]. However, the high propensity of
HIV-1 to develop drug resistance often leads to treatment
failure and progressive exhaustion of treatment options. As a
consequence, continuous surveillance of antiretroviral drug
resistance in large cohorts is warranted [2–5]. In an analysis
of patients failing cART in Italy between 1999 and 2006, we
previously found that the prevalence of any drug resistance
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was independently predicted by past exposure to suboptimal
regimens, number of regimens experienced, use of non-
nucleoside reverse transcriptase inhibitors (NNRTI) at fail-
ure, as well as by viral load [6]. Resistance to nucleoside
reverse transcriptase inhibitors (NRTI) peaked in 2002 (84%)
and declined thereafter (68% in 2006); resistance to NNRTI
peaked in 2004 (53%) but remained stable in later years
(48% in 2006); resistance to protease inhibitors (PI) peaked
in 2001 (52%) and declined thereafter (43% in 2006) [6].
During more recent years, new drug classes and active
agents belonging to the previously available classes have been
licensed [7–12]. Data on the proportion of patients develop-
ing resistance to the historical and to the new drug classes
after the introduction of these new agents into clinical prac-
tice are still limited. The aim of this study was to analyse the
prevalence of HIV-1 drug resistance to the historical drug
classes after treatment failure in Italy in the period 2007–
2009.
Methods
Patients failing any cART regimen between 2007 and 2009,
for whom complete treatment history, viro-immunological
parameters, and a genotypic resistance test at failure were
available, were selected from the Antiretroviral Resistance
Cohort Analysis (ARCA, http://www.hivarca.net) observa-
tional database [13]. Genotypic resistance tests considered
included reverse transcriptase and protease sequences. Each
cART failure was regarded as a distinct event. For patients
with more than one genotypic resistance test performed
during the same calendar year, only the most recent
sequence was considered. Resistance mutations were identi-
ﬁed according to the International AIDS Society-USA-2009
reference, considering only major resistance mutations [14].
Changes in the prevalence of drug resistance or differences
in continuous variables over calendar years were analysed
using either chi-squared test for trend or analysis of variance.
Predictors of the presence of three-class drug resistance
were analysed by multivariable logistic regression, including
variables showing a univariable signiﬁcant association
(p <0.05). All analyses were performed using the SPSS v.18
software (Chicago, IL).
Results
Based on the inclusion criteria, 1016 patients were selected:
570 genotypic resistance tests were performed in 2007, 257
in 2008, and 189 in 2009. Of these patients, 67% were male
and the most represented transmission categories were 36%
heterosexual subjects, 32% injecting drug users and 16% men
who have sex with men. At genotyping, the median age was
40 years (interquartile range (IQR) 39–48), the median viral
load was 4.00 log10 copies/mL (IQR 3.18–4.63), and the med-
ian CD4 cell count was 334 cells/lL (IQR 208–470). Patients
had experienced a median of 4 (IQR 2–7) cART regimens
(combination of ‡3 antiretrovirals) during a median time on
cART of 125 months (IQR 86–158); 63% had also experi-
enced a suboptimal antiretroviral regimen (mono/dual NRTI).
The proportion of patients administered and failing a new
(a)
(b)
FIG. 1. (a) Evolution of antiretroviral drug usage in failing regimens
from 2007 to 2009. (b) Evolution of the prevalence of resistance (at
least one major IAS-2009 mutation) to any nucleoside reverse trans-
criptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhib-
itor (NNRTI), protease inhibitor (PI) and non-B subtypes by calendar
year from 2007 to 2009. n, number of cases used as denominator;
TA, thymidine analogues (zidovudine/stavudine); Non-TA, (abacavir/
didanosine/tenofovir); rtv, ritonavir; FI, fusion inhibitor; EI, entry inhi-
bitor; INI, Integrose inhibitor.
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thymidine analogue (zidovudine/stavudine), non-thymidine
analogue (abacavir/didanosine/tenofovir), or other classes is
shown in Fig. 1(a). The evolution of patients’ characteristics
over calendar years is summarized in Table 1. The propor-
tion of male patients, of injecting drug users, of ﬁrst-line fail-
ures in the tested population, as well as the use of prior
mono- or dual NRTI therapies, the HIV-1 RNA and CD4 cell
counts at testing did not show signiﬁcant changes over time.
The prevalence of drug resistance to any drug class was 70%
in 2007 and 66% in 2009 (p 0.40). The proportion with
three-class resistance was 21% in 2007 and 14% in 2009
(p 0.06 for three-class). The proportion of tested patients
with any major International AIDS Society mutation associ-
ated with NRTI resistance, NNRTI resistance and PI resis-
tance evolved from 65%, 36% and 39% in 2007 to 56%, 31%
and 27% in 2009, (p 0.04 for change with NRTI; p 0.32 for
NNRTI; p 0.006 for PI), as shown in Fig. 1(b). In a multivari-
able model adjusting for duration of cART, CD4 counts, cur-
rent use of maraviroc, thymidine analogues and raltegravir,
the predictors of three-class resistance were the number of
cART regimens experienced (per additional regimen, OR
1.06, 95% CI 1.01–1.12, p 0.013), previous suboptimal ther-
apy (OR 2.01, 95% CI 1.14–3.56, p 0.016), and the current
use of ritonavir-boosted PI (OR 1.64, 95% CI 1.07–2.52,
p 0.024).
Discussion
The population of patients failing on cART in recent years in
Italy was mainly composed of subjects with extensive pre-
treatment, including a frequent remote history of mono/dual
NRTI therapy. During the 3 years analysed (2007–2009), the
prevalence of resistance to NRTI and PI decreased, as previ-
ously observed in the same cohort during the years 1999–
2006 [6]. The population analysed in the previous study
overlaps with the current one because of the periodic
updates of ARCA, and overall results indicate that there has
been a consistent trend towards a lower prevalence of resis-
tance to the three historical antiretroviral drug classes over
the last decade. This underlines the progress made with new
antiretroviral regimens, which allow suppression of viral rep-
lication in patients carrying resistant viruses and are more
resilient to the development of drug resistance. Only 189
patients were tested for resistance in 2009, and they may be
somehow unusual. Although no signiﬁcant differences were
found among patients across calendar years for the rate of
ﬁrst failure or median number of prior regimens, there could
be a difference for the number of failing regimens in the
treatment history.
Resistance to three-classes in this heavily drug-experi-
enced patient population maintained a stable prevalence dur-
ing 2007–2009 and was predicted by the number of cART
regimens experienced, prior suboptimal NRTI therapy and
the current use of ritonavir-boosted PI. Clearly, resistance
to multiple drug classes is a concern, given the impact shown
on clinical progression [15,16]. Surveillance of resistance to
novel drug classes in clinical practice must be warranted to
provide maximum beneﬁt from the availability of innovative
antiretroviral compounds, especially to inhibition entry and
integrase inhibitors [17,18].
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TABLE 1. Characteristics of treatment-experienced patients undergoing HIV-1 drug resistance testing at treatment failure
and their modiﬁcation over calendar years 2007–2009
2007 2008 2009 p-valuea
Age (years), median (IQR) 43 (39–47) 44 (39–48) 45 (40–50) 0.34
Gender, males (%) 67 68 64 0.48
Risk group (sex/IDU) (%) 51/30 49/34 50/32 0.61
Prior suboptimal therapy (%) 63 65 59 0.41
Median (IQR) number of prior cART regimens 4 (2–7) 5 (2–8) 4 (2–7) 0.17
First line cART failure (%) 14 8 17 0.86
Median (IQR) HIV-1 RNA (log copies/mL) 4.03 (3.24–4.62) 4.04 (3.20–4.68) 4.04 (3.20–4.68) 0.23
Median (IQR) CD4 (cells/mm3) 338 (222–471) 304 (187–456) 362 (202–465) 0.58
aContinuous variables were compared using analysis of variance, categorical variables were compared with chi-squared test for trend.
cART, combination antiretroviral therapy; HIV-1, human immunodeﬁciency virus type 1; IDU, injecting drug user; IQR, interquartile range; HAART, highly active antiretroviral
therapy.
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Abstract
Inﬂuenza virus is prone to mutations that may alter the intensity
of subsequent waves of infection. In this study, we evaluated
whether outcomes were different in the two waves of the
inﬂuenza A (H1N1) 2009 pandemic in patients admitted to the
intensive-care unit. Age, gender, lag-time to presentation and
APACHE-II scores were similar in both waves. Although ventila-
tory requirements were similar (36/37 vs. 36/39), non-signiﬁcant
reductions in the durations (days) of ventilation (10.3 ± 8.0
vs. 7.8 ± 9.4, p 0.11) and hospitalization (14.9 ± 10.5 vs.
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